ABSTRACTS OF DECISIONS
DECISION OF A DELEGATE OF THE COMMISSIONER OF PATENTS
Application : No. 721477 in the name of PROSIDION LIMITED
Title: Use of Dipeptidyl Peptidase IV Effectors for Lowering the Blood Glucose Level in Mammals
Action: Opposition by NOVO NORDISK under Section 104 of the Patents Act 1990
Decision: Issued 28 February 2006 .
Abstract
The claims of the specification as accepted are in the Swiss-style, directed to the use of activity lowering effectors of Dipeptidyl Peptidase (DP IV), or of DP IV-like enzyme activity, for the preparation of a medicament for lowering elevated blood glucose levels. The applicant sought to amend the specification to add claims to a method of lowering elevated blood glucose levels by the administration of a therapeutically effective amount of activity lowering effectors of Dipeptidyl Peptidase (DP IV), or of DP IV-like enzyme activity.
The opponent opposed the allowance of the amendments on the grounds that (i) the claims after amendments would not fall within the scope of the claims before amendment, and (ii) the amended claims would not satisfy the requirements of Section 40 because they would not be succinct.
After considering the European and New Zealand decisions relevant to interpreting Swiss-style claims the delegate concluded that in the Australian jurisdiction they should be construed consistently with accepted international practice i.e. these claims are directed to the manufacture of a medicament wherein the medicament is intended for a specified medical treatment, but do not extend to the method of medical treatment itself.
In relation to the present case, applying the “Distiller’s test” to this construction of the claims as accepted, the subject matter of proposed amended Claims 8 to 14 would not fall within the scope of accepted Claims 1 to 7 at acceptance because the latter do not encompass methods of treatment. Consequently the proposed amendments are not allowable under Section 102(2)(a).
The opposition was successful and costs were awarded against the applicant.
PATENTS ACT 1990
DECISION OF A DELEGATE OF THE COMMISSIONER OF PATENTS
Re:Patent Application No. 721477 by PROSIDION LIMITED and Opposition thereto by NOVO NORDISK under Section 104 of the Patents Act 1990
BACKGROUND
15. Patent 721477 was filed in the name of PROBIODRUG GESELLSCHAFT FUR ARZNEIMITTELFORSCHUNG MBH as PCT/DE/00820 under the Patent Cooperation Treaty on 24 April 1997 claiming priority from DE 97/19616486 dated 25 April 1996. The application entered the National Phase in Australia on 30 October 1998 under application number 30233/97 and was advertised accepted on 6 July 2000. A Notice of Opposition under Section 59 was filed on 5 October 2000. The applicant subsequently changed its name to PROBIODRUG AG which was recorded on the application on 21 October 2002.
16. The applicant filed a request to amend the patent under Section 104 on 9 December 2002. The opponent filed comments in relation to this request under Reg. 10.2(7) on 6 March 2003. The applicant responded to these comments on 10 April 2003 and the request was granted on 17 April…
Keep reading for free
Create a free CaseChat account to read Prosidion Limited v Novo Nordisk (Corrected Version) and more:
- Read every judgment in full
- Ask AI and get answers linked to paragraphs
- See how each paragraph was cited in later cases
- Download judgments as PDF or Word
One click creates your free account or signs you in.
By continuing you agree to the Terms and Privacy Policy.
- Case
- [2006] APO 6
- Decision Date
CaseChat Overview and Summary
The decision underscores the importance of claim construction in patent law, highlighting the need for consistency in interpreting claim forms across jurisdictions to provide clarity and certainty. The Delegate's conclusion that Swiss-style claims are not intended to extend to the method of medical treatment itself, but rather to the manufacture of a medicament for a specific use, aligns with broader international practices and aims to balance the protection of inventions with public policy considerations. This case reinforces the principle that amendments to a patent specification must not extend the scope of the original claims and must meet the requirements of clarity and succinctness under the Patents Act 1990.
Orders
Orders of the court
Full text does not contain this section.
Background
Background to the litigation
Full text does not contain this section.
Evidence
Evidence Before The Court
Full text does not contain this section.
Decision
Reasons for decision
Full text does not contain this section.
Ratio Decidendi
Legal Principle Established
Full text does not contain this section.